Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

Cell Death and Disease

Volumn 5, Issue 7, 2014, Pages

  Yu, H C ^a   Hung, M H ^b,c   Chen, Y L ^d,e   Chu, P Y ^f,g   Wang, C Y ^h   Chao, T T ^h   Liu, C Y ⁱ   Shiau, C W ⁱ   Chen, K F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f School of Medicine Kaohsiung Medical University ^*  (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^h FU JEN CATHOLIC UNIVERSITY   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; ERLOTINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN; PROTEIN KINASE B; SORAFENIB; TD 52; TRANSCRIPTION FACTOR ELK 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT DURATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905435273     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.325     Document Type: Article

References (48)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005; 42: 1208-1236
5. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 2014; 346: 17-23
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127
7. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858
8. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dualaction inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
11. Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB et al. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology (Baltimore, MD) 2008; 48: 1128-1137
12. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1067
13. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663
14. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-589
15. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4: 2957-2966.
16. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 2013; 85: 356-366
17. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Böttzauw T et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62
18. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007; 130: 21-24
19. Janssens V, Goris J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-439
20. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-965
21. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ et al. Overexpression and small moleculetriggered downregulation of CIP2A in lung cancer. PloS One 2011; 6: e20159
22. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-6266
23. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012; 14: R68
24. He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012; 21: 143-149
25. Huang P, Qiu J, You J, Hong J, Li B, Zhou K et al. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 2012; 17: 422-429
26. Pallai R, Bhaskar A, Sodi V, Rice LM. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 2012; 3: 323-335
27. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160
28. Chen W, Wang Z, Jiang C, Ding Y. PP2A-mediated anticancer therapy. Gastroenterol Res Pract 2013; 2013: 675429
29. Fujiki H, Suganuma M. Unique features of the okadaic acid activity class of tumor promoters. J Cancer Res Clin Oncol 1999; 125: 150-155
30. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013; 335: 9-18
31. Khanna A, Pimanda JE,Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 2013; 73: 6548-6553
32. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH et al. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 2013; 98: 729-738
33. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30: 2504-2513
34. Yu LG, Packman LC, Weldon M, Hamlett J, Rhodes JM. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem 2004; 279: 41377-41383
35. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A. Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Nature 1991; 354: 531-534
36. Rao VN, Reddy ES. A divergent ets-related protein, elk-1, recognizes similar c-ets-1 proto-oncogene target sequences and acts as a transcriptional activator. Oncogene 1992; 7: 65-70
37. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80: 199-211
38. Wyrzykowska P, Stalinska K, Wawro M, Kochan J, Kasza A. Epidermal growth factor regulates PAI-1 expression via activation of the transcription factor Elk-1. Biochimica et Biophysica Acta 2010; 1799: 616-621
39. Yeh HY, Cheng SW, Lin YC, Yeh CY, Lin SF, Soo VW. Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency. BMC Med Genomics 2009; 2: 70
40. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piche A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 2012; 11: 84
41. Ying TH, Hsieh YH, Hsieh YS, Liu JY. Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells. Cell Biol Int 2008; 32: 210-216
42. Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J et al. Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer biologic profile and clinicopathologic features. Breast (Edinburgh, Scotland) 2013; 22: 89-95
43. Zhang X, Zhang B, Gao J,Wang X, Liu Z. Regulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikis. J Biol Chem 2013; 288: 32742-32752
44. Jin Q, Liu G, Domeier PP, Ding W, Mulder KM. Decreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells. PloS One 2013; 8: e66439
45. Sun NK, Huang SL, Chang TC, Chao CC. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3betadependent protein degradation. J Cell Biochem 2013; 114: 1819-1831
46. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology (Baltimore, MD) 2000; 32: 958-961
47. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/ Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001; 20: 2606-2610
48. Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh YS, Liu JY. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem Biophys Res Commun 2006; 339: 217-225